Dr. Claudia AM Fulgenzi is a dedicated professional in the field of oncology, currently being a PhD student at Imperial College in London and a Locum Consultant in Oncology at Chelsea and Westminster Hospital, also located in London.
Dr. Claudia AM Fulgenzi started her academic journey by earning a degree in medicine from the University of Rome Tor Vergata in Rome in 2017. Following her graduation, she pursued specialized training in Oncology at the University Campus Bio Medico of Rome in Italy. During this period, Dr. Fulgenzi honed her clinical expertise and developed a particular interest in gastrointestinal (GI) cancers, with a specific focus on hepatic-biliary malignancies.
In pursuit of further knowledge, Dr. Fulgenzi made the decision to move to London in 2021. After joining the esteemed academic community at Imperial College as research fellow, she was offered a PhD program focused on cancer-immunotherapy in October 2022.
In 2022, Dr. Fulgenzi was bestowed with the ASCO Merit Award, a prestigious recognition from the American Society of Clinical Oncology and with the Young Investigator award by the International Liver Cancer Association (ILCA) for her research in liver cancer. The following year, in 2023, she received a merit award by the American Society of Clinical Oncology as leading author of a sub-analysis of the IMbrave150 trial presented at the ASCO GI symposium, further solidifying her reputation as a rising star in the field of gastrointestinal oncology.
Simultaneously, Dr. Fulgenzi has been actively involved in clinical practice, serving as a Locum Consultant in Oncology at Chelsea and Westminster Hospital. In this role, she provides expert medical guidance and comprehensive care to patients battling cancer. Driven by a patient-centred approach, she strives to improve treatment outcomes and enhance the quality of life for those under her care.